Reported positive data from the escalation portion of Phase 1/2 study (COVALENT-111) in type 2 diabetes patients, displaying durable improved glycemic control while off therapy for 22 weeks,...
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (Biomea or the Company), a clinical stage biopharmaceutical company focused on the discovery and...
In 2023, reported Phase 2 data (COVALENT-111) in type 2 diabetes patients supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes: a loss of healthy,...
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes The first two type 1 diabetes patients enrolled in...
REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (Biomea or the Company), a clinical stage biopharmaceutical company focused on the discovery and...
Biomea Fusion Presents Patient Cohorts in COVALENT-111
Biomea Fusion Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Expansion portion of Phase II COVALENT-111 study readout in 216 patients with type 2 diabetes expected in 2024.Open label portion of Phase II COVALENT-112 study readout in 40 patients with type 1...
The clinical study, COVALENT-112, has initiated enrollment of adults living with type 1 diabetes in the US and Canada.Eligible patients include those who have been diagnosed with type 1 diabetes for...
REDWOOD CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Biomea) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel...